Evidence map›Paper›PMID 40779068›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Synthesis and preclinical evaluation of a

Longxin Lin, Yuki Mizuno, Yuki Shibata, Hironobu Yasui, Yuji Kuge

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The novel [RSC advances · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Longxin LinGraduate School of Biomedical Science and Engineering, Hokkaido University, Sapporo, 060-0815, Japan.
Yuki MizunoCentral Institute of Isotope Science, Hokkaido University, Sapporo, 060-0815, Japan. mizuno@ric.hokudai.ac.jp.ORCID 0000-0001-8740-2261
Yuki ShibataCentral Institute of Isotope Science, Hokkaido University, Sapporo, 060-0815, Japan.
Hironobu YasuiFaculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan.
Yuji KugeCentral Institute of Isotope Science, Hokkaido University, Sapporo, 060-0815, Japan.

Funding

Japan Science and Technology Agency JPMJSP2119Japan Society for the Promotion of Science 21H02858
6 · The paper itself

Abstract

purposeTransferrin receptor 1 (TfR1) is a transmembrane glycoprotein that mediates cellular iron uptake. Despite its potential as a target for tumor diagnosis, the lack of suitable TfR1 ligands has hindered the development of effective TfR1 imaging agents. We labeled a recently discovered TfR1 ligand, TfRB1G3, with Ga-68 and evaluated its potential for TfR1 imaging through preclinical experiments.

methodsTfRB1G3 was modified with HBED-CC and radiolabeled with

results[

conclusion[

Indexed as

Antigens, CDGallium RadioisotopesPeptidesPositron-Emission TomographyReceptors, TransferrinAnimalsCell Line, TumorChemistry Techniques, SyntheticHumansIsotope LabelingMiceTissue DistributionAntigens, CDCD71 antigenGallium-68Gallium RadioisotopesPeptidesReceptors, TransferrinCysteine-dense peptideGallium-68 (68Ga)Positron emission tomography (PET)Transferrin receptor (TfR)

Identifiers

PMID40779068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.